Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
230.5 EUR | +4.77% | +0.90% | -14.77% |
13/05 | Sartorius Partners With Sanofi for Biomanufacturing Platform | MT |
30/04 | SARTORIUS : Target cut by -6.1% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 76.62 and 53.4 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.77% | 19.25B | - | ||
-37.61% | 2.96B | C+ | ||
+23.79% | 1.96B | - | ||
+1.29% | 1.69B | - | ||
+33.13% | 1.27B | B+ | ||
-14.61% | 982M | - | ||
-20.31% | 913M | - | C- | |
+5.60% | 801M | - | ||
-24.68% | 630M | B+ | ||
+7.55% | 506M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SRT3 Stock
- SRT Stock
- Ratings Sartorius AG